Rigel Appoints Mark W. Frohlich, M.D. to Board of Directors

Core Insights - Rigel Pharmaceuticals has appointed Dr. Mark W. Frohlich to its Board of Directors, bringing over 25 years of experience in developing cellular immunotherapies for cancer treatment [1][2] - Dr. Frohlich's expertise includes clinical drug development, translational research, and portfolio strategy, which will support Rigel's hematology and oncology development pipeline [2][4] - He has previously held significant roles in various biotechnology companies, including as CEO of Indapta Therapeutics and leading portfolio strategy at Juno Therapeutics [2][3] Company Overview - Rigel Pharmaceuticals, Inc. is a biotechnology company focused on discovering and developing novel therapies for hematologic disorders and cancer [4] - The company was founded in 1996 and is based in South San Francisco, California [4] - Rigel aims to improve the lives of patients through its marketed products and pipeline of potential products [4]